Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EvoPAR-Prostate02: adjuvant saruparib after radiotherapy and androgen deprivation therapy in BRCA-mutated high-risk localized prostate cancer
CTR20254106Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of saruparib in prostate cancer (PCa) (4 cohorts), sponsored by AstraZeneca. Primary endpoint: Metastasis-free survival. Started Oct 2025; status: active.
02
Drugs
saruparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20254106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254106.